Dr. Seema Singhal, MD
Hematology (Hematology (Internal Medicine) Physician)
675 N Saint Clair St, Galter 21-100
Chicago, IL 60611
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 412
Licensed in Illinois since 2001, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
IL license 036104212 (first issued 2001; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northwestern Medicine Central Dupage Hospital Winfield, IL
- Northwestern Memorial Hospital Chicago, IL
- Northwestern Lake Forest Hospital Lake Forest, IL
- Palos Community Hospital Palos Heights, IL
- Northwestern Medicine Delnor Community Hospital Geneva, IL
Medical groups
- Northwestern Medical Faculty Foundation (4,503 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 412
- Services billed
- 2,443
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 3,600 | 16 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 1,180 | 15 |
| Established patient office or other outpatient visit, 40-54 minutes | 862 | 167 |
| Injection, bortezomib, 0.1 mg | 447 | 15 |
| Established patient office or other outpatient visit, 30-39 minutes | 196 | 132 |
| Injection, palonosetron hcl, 25 mcg | 170 | 14 |
| Telephone medical discussion with physician, 21-30 minutes | 164 | 91 |
| Injection, dexamethasone sodium phosphate, 1 mg | 152 | 15 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 74 | 11 |
| Injection of additional new drug or substance into vein | 49 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Chicago, IL | 197 |
| Revlimid (lenalidomide) | 173 |
| Pomalyst (pomalidomide) | 138 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Chicago, IL | 72 |
| Dexamethasone Other prescribers in Chicago, IL | 65 |
| Brukinsa (zanubrutinib) | 59 |
| Lenalidomide | 43 |
| Imbruvica (ibrutinib) | 25 |
| Ondansetron Odt (ondansetron) Other prescribers in Chicago, IL | 24 |
| Thalomid (thalidomide) | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 3 companies. The companies reported $228,580 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Celgene Corporation - A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma
Janssen Research & Development, LLC - A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Celgene Corporation - Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma
Janssen Research & Development, LLC - A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
E.r. Squibb & Sons, L.l.c. - Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commercial Release
E.r. Squibb & Sons, L.l.c. - Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commercial Release
Celgene Corporation - A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
E.r. Squibb & Sons, L.l.c. - A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.